{"id":61307,"date":"2026-03-25T21:58:39","date_gmt":"2026-03-25T13:58:39","guid":{"rendered":"https:\/\/flcube.com\/?p=61307"},"modified":"2026-03-25T21:58:40","modified_gmt":"2026-03-25T13:58:40","slug":"msd-reportedly-eyes-6-billion-terns-pharma-acquisition-bcr-abl-inhibitor-tern-701-targets-post-keytruda-oncology-pipelinew333333","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=61307","title":{"rendered":"MSD Reportedly Eyes $6 Billion Terns Pharma Acquisition \u2013 BCR-ABL Inhibitor TERN-701 Targets Post-Keytruda Oncology Pipelinew333333"},"content":{"rendered":"\n

Merck, Sharp & Dohme (MSD; NYSE: MRK<\/a>)<\/strong> is reportedly preparing to acquire Terns Pharmaceuticals (NASDAQ: TERN<\/a>)<\/strong> for USD 6 billion<\/strong>, according to Reuters<\/strong>. The potential transaction would deliver MSD a next-generation BCR-ABL allosteric inhibitor (TERN-701)<\/strong> with best-in-class Phase I data in chronic myeloid leukemia (CML)<\/strong>, addressing the pharma giant’s urgent need for new oncology stars<\/strong> as Keytruda (pembrolizumab)<\/strong> approaches its 2028 patent cliff<\/strong>.<\/p>\n\n\n\n

Acquisition Overview<\/h2>\n\n\n\n
Element<\/th>Detail<\/th><\/tr><\/thead>
Acquirer<\/strong><\/td>Merck, Sharp & Dohme (MSD; NYSE: MRK)<\/td><\/tr>
Target<\/strong><\/td>Terns Pharmaceuticals (Nasdaq: TERN)<\/td><\/tr>
Reported Value<\/strong><\/td>USD 6 billion<\/strong> (per Reuters)<\/td><\/tr>
Strategic Rationale<\/strong><\/td>Post-Keytruda oncology pipeline; TERN-701 BCR-ABL inhibitor<\/td><\/tr>
Current Terns Market Cap<\/strong><\/td>USD 5 billion<\/strong> (USD 50\/share, March 24, 2026 close)<\/td><\/tr>
Premium Implied<\/strong><\/td>~20% premium<\/strong> to trading price; ~14x<\/strong> November 2025 market cap pre-TERN-701 data<\/td><\/tr>
Status<\/strong><\/td>Rumored<\/strong> \u2013 neither MSD nor Terns has commented<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Terns Pharmaceuticals Strategic Pivot<\/h2>\n\n\n\n
Timeline<\/th>Strategic Shift<\/th>Pipeline Focus<\/th><\/tr><\/thead>
2016 (Founded)<\/strong><\/td>Chronic liver diseases \u2013 MASH, fibrosis, hepatocellular carcinoma<\/td>TERN-501 (MASH), liver oncology<\/td><\/tr>
February 2021<\/strong><\/td>Nasdaq IPO; USD 430M market cap<\/strong><\/td>Liver disease platform<\/td><\/tr>
Post-Setbacks<\/strong><\/td>Pivot to metabolic diseases<\/td>TERN-501 (MASH), TERN-601 (obesity)<\/strong><\/td><\/tr>
October 2025<\/strong><\/td>TERN-601 subpar Phase III data<\/strong> vs. GLP-1s; metabolic exit announced<\/td>Discontinued metabolic R&D<\/td><\/tr>
November 2025<\/strong><\/td>TERN-701 Phase I breakthrough<\/strong> \u2013 CML best-in-class data<\/td>Exclusive oncology focus<\/strong> \u2013 BCR-ABL allosteric inhibition<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

TERN-701 Clinical Differentiation<\/h2>\n\n\n\n
Endpoint<\/th>TERN-701 Phase I Result<\/th>Competitive Context<\/th><\/tr><\/thead>
Major Molecular Response (MMR)<\/strong><\/td>60\u201370%<\/strong> in asciminib\/TKI-failure patients<\/td>\u22652x historical rates<\/strong> with existing products<\/td><\/tr>
Patient Population<\/strong><\/td>Chronic myeloid leukemia (CML) \u2013 resistant\/refractory to prior TKIs<\/td>High unmet need; ponatinib\/asciminib limitations<\/td><\/tr>
Safety Profile<\/strong><\/td><10% Grade \u22653 adverse events<\/strong>; broad therapeutic window<\/td>Improved tolerability vs. multi-TKI resistance settings<\/td><\/tr>
Stock Impact<\/strong><\/td>+80% surge<\/strong> at November 2025 market open<\/td>Validation of best-in-class potential<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

MSD Oncology Strategy & Acquisition Context<\/h2>\n\n\n\n
Factor<\/th>Strategic Implication<\/th><\/tr><\/thead>
Keytruda Patent Cliff<\/strong><\/td>2028 U.S. LOE<\/strong> \u2013 $25+ billion at risk<\/strong>; urgent replacement needed<\/td><\/tr>
Recent M&A Activity<\/strong><\/td>January 2026 \u2013 Revolution Medicines deal abandoned<\/strong> (pricing disagreement); active pursuit of oncology assets continues<\/td><\/tr>
TERN-701 Fit<\/strong><\/td>Allosteric BCR-ABL inhibition<\/strong> \u2013 differentiated mechanism vs. ATP-competitive TKIs; addresses resistant CML<\/strong> and Ph+ ALL<\/strong> expansion<\/td><\/tr>
Commercial Synergy<\/strong><\/td>MSD’s oncology sales force<\/strong> (Keytruda infrastructure) supports rapid TERN-701 launch; hospital oncology<\/strong> relationships accelerate adoption<\/td><\/tr>
Pipeline Optionality<\/strong><\/td>Terns oncology platform (beyond TERN-701) provides early-stage bolt-ons<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Market Context & Valuation Analysis<\/h2>\n\n\n\n
Metric<\/th>Terns Pharma Trajectory<\/th><\/tr><\/thead>
IPO Market Cap (Feb 2021)<\/strong><\/td>USD 430 million<\/td><\/tr>
Pre-TERN-701 Data (Oct 2025)<\/strong><\/td>~USD 1\u20131.5 billion (metabolic failure discount)<\/td><\/tr>
Post-TERN-701 Data (Nov 2025)<\/strong><\/td>USD 2.5\u20133 billion (+80% spike)<\/td><\/tr>
Current Market Cap (Mar 2026)<\/strong><\/td>USD 5 billion<\/strong> (ongoing CML data optimism)<\/td><\/tr>
MSD Reported Offer<\/strong><\/td>USD 6 billion<\/strong> (~20% premium)<\/td><\/tr>
Deal Multiple<\/strong><\/td>~12x current revenue<\/strong> (pre-commercial); ~6x peak sales potential<\/strong> assuming CML + Ph+ ALL approval<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Forward\u2011Looking Statements<\/strong>
This brief contains forward\u2011looking statements based on unconfirmed market rumors regarding the MSD-Terns acquisition. Actual transaction terms, closing probability, and strategic outcomes may differ due to due diligence findings, competitive bidding, regulatory considerations, and TERN-701 Phase II\/III clinical outcomes. Neither MSD nor Terns has confirmed discussions.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Merck, Sharp & Dohme (MSD; NYSE: MRK) is reportedly preparing to acquire Terns Pharmaceuticals (NASDAQ:…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[16,2675,176,1032,903,235],"class_list":["post-61307","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-cancer","tag-merck-sharp-dohme","tag-msd","tag-nasdaq-tern","tag-nyse-mrk","tag-terns-pharmaceuticals"],"yoast_head":"\nMSD Reportedly Eyes $6 Billion Terns Pharma Acquisition \u2013 BCR-ABL Inhibitor TERN-701 Targets Post-Keytruda Oncology Pipelinew333333 - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Merck, Sharp & Dohme (MSD; NYSE: MRK) is reportedly preparing to acquire Terns Pharmaceuticals (NASDAQ: TERN) for USD 6 billion, according to Reuters. The potential transaction would deliver MSD a next-generation BCR-ABL allosteric inhibitor (TERN-701) with best-in-class Phase I data in chronic myeloid leukemia (CML), addressing the pharma giant's urgent need for new oncology stars as Keytruda (pembrolizumab) approaches its 2028 patent cliff.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=61307\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"MSD Reportedly Eyes $6 Billion Terns Pharma Acquisition \u2013 BCR-ABL Inhibitor TERN-701 Targets Post-Keytruda Oncology Pipelinew333333\" \/>\n<meta property=\"og:description\" content=\"Merck, Sharp & Dohme (MSD; NYSE: MRK) is reportedly preparing to acquire Terns Pharmaceuticals (NASDAQ: TERN) for USD 6 billion, according to Reuters. The potential transaction would deliver MSD a next-generation BCR-ABL allosteric inhibitor (TERN-701) with best-in-class Phase I data in chronic myeloid leukemia (CML), addressing the pharma giant's urgent need for new oncology stars as Keytruda (pembrolizumab) approaches its 2028 patent cliff.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=61307\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-25T13:58:39+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-25T13:58:40+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61307#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61307\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"MSD Reportedly Eyes $6 Billion Terns Pharma Acquisition \u2013 BCR-ABL Inhibitor TERN-701 Targets Post-Keytruda Oncology Pipelinew333333\",\"datePublished\":\"2026-03-25T13:58:39+00:00\",\"dateModified\":\"2026-03-25T13:58:40+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61307\"},\"wordCount\":474,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Cancer\",\"Merck Sharp & Dohme\",\"MSD\",\"NASDAQ: TERN\",\"NYSE: MRK\",\"Terns Pharmaceuticals\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=61307#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61307\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=61307\",\"name\":\"MSD Reportedly Eyes $6 Billion Terns Pharma Acquisition \u2013 BCR-ABL Inhibitor TERN-701 Targets Post-Keytruda Oncology Pipelinew333333 - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-03-25T13:58:39+00:00\",\"dateModified\":\"2026-03-25T13:58:40+00:00\",\"description\":\"Merck, Sharp & Dohme (MSD; NYSE: MRK) is reportedly preparing to acquire Terns Pharmaceuticals (NASDAQ: TERN) for USD 6 billion, according to Reuters. The potential transaction would deliver MSD a next-generation BCR-ABL allosteric inhibitor (TERN-701) with best-in-class Phase I data in chronic myeloid leukemia (CML), addressing the pharma giant's urgent need for new oncology stars as Keytruda (pembrolizumab) approaches its 2028 patent cliff.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61307#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=61307\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61307#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MSD Reportedly Eyes $6 Billion Terns Pharma Acquisition \u2013 BCR-ABL Inhibitor TERN-701 Targets Post-Keytruda Oncology Pipelinew333333\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"MSD Reportedly Eyes $6 Billion Terns Pharma Acquisition \u2013 BCR-ABL Inhibitor TERN-701 Targets Post-Keytruda Oncology Pipelinew333333 - Insight, China's Pharmaceutical Industry","description":"Merck, Sharp & Dohme (MSD; NYSE: MRK) is reportedly preparing to acquire Terns Pharmaceuticals (NASDAQ: TERN) for USD 6 billion, according to Reuters. The potential transaction would deliver MSD a next-generation BCR-ABL allosteric inhibitor (TERN-701) with best-in-class Phase I data in chronic myeloid leukemia (CML), addressing the pharma giant's urgent need for new oncology stars as Keytruda (pembrolizumab) approaches its 2028 patent cliff.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=61307","og_locale":"en_US","og_type":"article","og_title":"MSD Reportedly Eyes $6 Billion Terns Pharma Acquisition \u2013 BCR-ABL Inhibitor TERN-701 Targets Post-Keytruda Oncology Pipelinew333333","og_description":"Merck, Sharp & Dohme (MSD; NYSE: MRK) is reportedly preparing to acquire Terns Pharmaceuticals (NASDAQ: TERN) for USD 6 billion, according to Reuters. The potential transaction would deliver MSD a next-generation BCR-ABL allosteric inhibitor (TERN-701) with best-in-class Phase I data in chronic myeloid leukemia (CML), addressing the pharma giant's urgent need for new oncology stars as Keytruda (pembrolizumab) approaches its 2028 patent cliff.","og_url":"https:\/\/flcube.com\/?p=61307","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-03-25T13:58:39+00:00","article_modified_time":"2026-03-25T13:58:40+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=61307#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=61307"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"MSD Reportedly Eyes $6 Billion Terns Pharma Acquisition \u2013 BCR-ABL Inhibitor TERN-701 Targets Post-Keytruda Oncology Pipelinew333333","datePublished":"2026-03-25T13:58:39+00:00","dateModified":"2026-03-25T13:58:40+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=61307"},"wordCount":474,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Cancer","Merck Sharp & Dohme","MSD","NASDAQ: TERN","NYSE: MRK","Terns Pharmaceuticals"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=61307#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=61307","url":"https:\/\/flcube.com\/?p=61307","name":"MSD Reportedly Eyes $6 Billion Terns Pharma Acquisition \u2013 BCR-ABL Inhibitor TERN-701 Targets Post-Keytruda Oncology Pipelinew333333 - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-03-25T13:58:39+00:00","dateModified":"2026-03-25T13:58:40+00:00","description":"Merck, Sharp & Dohme (MSD; NYSE: MRK) is reportedly preparing to acquire Terns Pharmaceuticals (NASDAQ: TERN) for USD 6 billion, according to Reuters. The potential transaction would deliver MSD a next-generation BCR-ABL allosteric inhibitor (TERN-701) with best-in-class Phase I data in chronic myeloid leukemia (CML), addressing the pharma giant's urgent need for new oncology stars as Keytruda (pembrolizumab) approaches its 2028 patent cliff.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=61307#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=61307"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=61307#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"MSD Reportedly Eyes $6 Billion Terns Pharma Acquisition \u2013 BCR-ABL Inhibitor TERN-701 Targets Post-Keytruda Oncology Pipelinew333333"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/61307","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=61307"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/61307\/revisions"}],"predecessor-version":[{"id":61312,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/61307\/revisions\/61312"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=61307"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=61307"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=61307"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}